These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34519227)

  • 1. Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis.
    Akdogan N; Dogan S; Bostan E; Gulseren D; Yalici-Armagan B; Elcin G; Evans SE; Karaduman A; Atakan N
    Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1535-1541. PubMed ID: 34519227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
    Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
    JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching biologics in children with psoriasis: Results from the BiPe cohort.
    Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
    Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
    Bayaraa B; Imafuku S
    J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological Retention Rates, the Reasons of Switching, and Prognostic Factors in Patients with Psoriasis Treated Biologics.
    Tokuyama M; Ota M; Saitoh R; Sawamura M; Okitsu N; Shimizu T; Kondoh A; Yamaoka H; Mabuchi T
    Tokai J Exp Clin Med; 2020 Dec; 45(4):230-235. PubMed ID: 33300595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience.
    Özkur E; Kıvanç Altunay İ; Oğuz Topal İ; Aytekin S; Topaloğlu Demir F; Özkök Akbulut T; Kara Polat A; Karadağ AS
    Dermatology; 2021; 237(1):22-30. PubMed ID: 31865339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment persistence of biologics among patients with psoriatic arthritis.
    Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D
    Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.
    Curmin R; Guillo S; De Rycke Y; Bachelez H; Beylot-Barry M; Beneton N; Chosidow O; Dupuy A; Joly P; Jullien D; Richard MA; Viguier M; Sbidian E; Paul C; Mahé E; Tubach F;
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2101-2112. PubMed ID: 35793473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching of biologics in psoriasis: Reasons and results.
    Honda H; Umezawa Y; Kikuchi S; Yanaba K; Fukuchi O; Ito T; Nobeyama Y; Asahina A; Nakagawa H
    J Dermatol; 2017 Sep; 44(9):1015-1019. PubMed ID: 28488283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
    Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
    Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.
    Graier T; Salmhofer W; Jonak C; Weger W; Kölli C; Gruber B; Sator PG; Prillinger K; Mlynek A; Schütz-Bergmayr M; Richter L; Ratzinger G; Painsi C; Selhofer S; Häring N; Wippel-Slupetzky K; Skvara H; Trattner H; Tanew A; Inzinger M; Tatarski R; Bangert C; Ellersdorfer C; Lichem R; Gruber-Wackernagel A; Hofer A; Legat F; Schmiedberger E; Strohal R; Lange-Asschenfeldt B; Schmuth M; Vujic I; Hoetzenecker W; Trautinger F; Saxinger W; Müllegger R; Quehenberger F; Wolf P
    Br J Dermatol; 2021 Jun; 184(6):1094-1105. PubMed ID: 33289075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting.
    Gulliver WP; Randell S; Gulliver S; Gregory V; Nagle S; Chambenoit O
    J Cutan Med Surg; 2018; 22(6):567-576. PubMed ID: 29952225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug survival in patients with psoriasis is associated with the availability of biologic medications.
    Shalom G; Cohen AD; Feldhamer I; Comaneshter D; Freud T; Pavlovsky L
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1524-1528. PubMed ID: 31953883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study.
    Cozzani E; Wei Y; Burlando M; Signori A; Parodi A
    J Am Acad Dermatol; 2020 Jan; 82(1):37-44. PubMed ID: 31150706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Disease Factors of Patients with Psoriasis and Psoriatic Arthritis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.
    Mease PJ; Blauvelt A; Sima AP; Beaty SW; Low R; Gomez B; Gurrola M; Lebwohl MG
    Dermatol Ther (Heidelb); 2024 Oct; 14(10):2805-2825. PubMed ID: 39283415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.